Aimmune’s Palforzia Gains US FDA Panel Nod But Faces REMS Restrictions

 
• By Sue Sutter
  
FDA Advisory Committee Feature image
Palforzia garnered favorable AdComm votes on efficacy and safety.
Pink Sheet Podcast

Have you checked out Pink Sheet podcast?

New episodes every Thursday.

SpotifyApple PodcastsWebsite

More from US FDA Performance Tracker

More from Regulatory Trackers